CompletedEarly Phase 1

The Effects of ∆-9-THC and Naloxone in Humans

United States6 participantsStarted 2011-11-04

Plain-language summary

The purpose of this project is to examine the effects of mu-opiate antagonism on the rewarding and reinforcing effects of delta-9-tetrahydrocannabinol (THC), the main psychoactive ingredient of cannabis.

Who can participate

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * At least one exposure to Cannabis Exclusion Criteria: * Cannabis Naive

What they're measuring

Behavioral Measures

Timeframe: 4 test days

Trial details

NCT IDNCT01591629

SponsorYale University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-06-01

View on ClinicalTrials.gov More Healthy trials